For US Healthcare Professionals Only
Filter
Interpreting patient health-related quality-of-life experience with zilucoplan treatment in generalized myasthenia gravis in RAISE and RAISE-XT
Effect of zilucoplan on fatigue in patients with generalized myasthenia gravis: RAISE-XT 120-week follow-up
Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: A post hoc analysis of final pooled Phase 3 data
Response to rozanolixizumab in patients with generalized myasthenia gravis: Final pooled analysis of MycarinG and open‑label extension studies
Educational needs assessment of nurses involved in the care of patients with myasthenia gravis
Characteristics of patients with generalized myasthenia gravis initiating rozanolixizumab treatment in the United States
Real-world insights from people living with myasthenia gravis: Analysis of user characteristics and adherence patterns from the HumaMG ap
Sustained minimal symptom expression in generalized myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
Repeated cycles of rozanolixizumab treatment in patients with anti-muscle-specific tyrosine kinase antibody-positive generalized myasthenia gravis
Long-term safety of cyclic rozanolixizumab treatment in patients with generalized myasthenia gravis: A final analysis of Phase 3 studies
Zilucoplan treatment of severe exacerbations leading to hospitalization in generalized myasthenia gravis: Study design
The long-term effectiveness of zilucoplan in myasthenia gravis: Predictive modeling in a US real-world database
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study
Measuring the effect of rozanolixizumab treatment in the MycarinG study using the Myasthenia Gravis Impairment Index